PARIS--(BUSINESS WIRE)--Regulatory News :
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA FR0010609263), leader in the optical biopsy market and maker of Cellvizio, the fastest way to see cancer, today announced that physicians around the world will soon have access to a new Optical Biopsy platform through the launch of EVA, the Endomicroscopy Virtual Assistant, dedicated to provide a seamless Cellvizio experience from image acquisition to review and documentation in the patient's health record. EVA is powered by the new Cellvizio software, today available for sale in Europe and in the USA for digestive, pulmonary and urological applications*.
EVA enables efficient management of Optical Biopsy procedures with greater workflow productivity, clinical value and integration:
- An increased confidence for physicians using Cellvizio: EVA's SmartReview™ highlights the stable segments within Cellvizio videos for a streamlined Optical Biopsy procedure review. Moreover, with FastExtract™, EVA permits an immediate selection of the video clips identified by SmartReview™. Finally, EVA's Atlas provides reference videos for each organ and pathology, directly available on the Cellvizio system.
- A way to share Cellvizio within the hospital: EVA's DICOM connectivity facilitates integration of Cellvizio into the hospital information system for digital archiving and transmission of Optical Biopsy data all over the hospital. With QuickReport™, through an easy-to-use template, EVA generates print-ready reports for the patient’s electronic health record.
- An improved access to Cellvizio: through a redesigned user interface, EVA allows physicians to make annotations on images, and provides a remote service solution for better assistance.
”This impressive improvement will significantly facilitate our usage of Optical Biopsy”, commented Dr. David Carr-Locke, Chief, Division of Digestive Diseases, Beth Israel Medical Center, New York, an early adopter of the Cellvizio system who helped design EVA. “With EVA, I believe that endoscopy and surgery will never be the same again.”
EVA's availability is the first milestone towards the launch of the expected “Smart Atlas”, a unique extensive library of Optical Biopsy references coupled to a proprietary image recognition algorithm, which will assist the physicians in their Optical Biopsy interpretation.
“Mauna Kea Technologies has always made integration and physician's confidence a top priority, as both are critical to the adoption of Optical Biopsy. Our development efforts are aligned towards making Optical Biopsy a standard of care procedure”, said Sacha Loiseau, CEO of Mauna Kea Technologies. “Starting today, EVA will enhance the endoscopic and surgical experience, and engage physicians on a deeper, more impactful level in the way they use Optical Biopsy for managing their patients.”
For more information, please check the following webpage:
http://www.maunakeatech.com/patients/47/product-spotlight
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
* Urological applications for Cellvizio have not yet been cleared by the U.S. Food and Drug Administration.
